I
n secondary lymphoid organs, mature B cells express membrane immunoglobulin (Ig) of M and D isotypes (IgM and IgD, respectively) of the same specificity through alternative splicing of a pre-mRNA encompassing the VDJ variable region and C μ and C δ heavy chain constant exons. 1 After encountering antigen, B cells undergo class switch recombination (CSR) by which the C μ gene is substituted with C γ , C ε or C α , thereby generating IgG, IgE and IgA antibodies of the same antigenic specificity but with new effector functions. CSR requires the DNA-editing enzyme activation-induced deaminase (AID), which targets switch (S) regions preceding C μ (namely, the S μ donor region) and C γ , C ε and C α genes (namely, the S γ,ε,α acceptor regions). 1 CSR is controlled in trans through a wide spectrum of enzymes and proteins and in cis through the immunoglobulin heavy chain (IgH) 3′ regulatory region (3′RR) super-enhancer that specifically AID-poises the S acceptor but not the S μ donor region. 2 IgD CSR is a rare and enigmatic event restricted to a few B-cell subsets in specific lymphoid tissues (such as mesenteric lymph nodes, peritoneal cavity and mucosa-associated tissue) in both mice and humans. [3] [4] [5] A recent study suggested that IgD CSR is initiated by microbiota, 5 demonstrating a role for IgD in the homeostatic regulation of the microbial community. The mechanistic regulation of IgD CSR remains enigmatic, reflecting the difficulty to obtain a sufficient number of S μ -σ δ (σ for S-like) junction sequences for molecular analysis. We recently reported a new computational tool (CSReport) for the automatic analysis of CSR junctions sequenced using high-throughput sequencing, 6 and we used this tool to analyze S μ -σ δ junctions in wild-type (wt) mice. 7 Genomic deletion of the 3′RR super-enhancer abrogates CSR to IgG, IgE and IgA classes. 2, 8 In contrast, a unique study, based on the analysis of a few S μ -σ δ junctions, reported the 3′RR super-enhancer as dispensable for IgD CSR. 4 We thus used CSReport and highthroughput sequencing to conduct a more in depth analysis of S μ -σ δ junctions in 3′RR-deficient mice.
The present study was approved by our local ethics committee review board (Comité Régional d'Ethique sur l'Expéri-mentation Animale du Limousin, Limoges, France) and conducted according to the European guidelines for animal experimentation. Peritoneal cavity 3'RR-deficient mouse B cells were used for these experiments. In some experiments, 3′RR-deficient mice were pristane-treated (1 ml) for 2 months to induce inflammation prior to the recovery of peritoneal cavity cells. As previously described in detail, 4 junctions were amplified using touchdown PCR followed by nested PCR. Libraries of 200 bp were prepared from the 1-2 kb PCR products of S μ -σ δ amplification for ion proton sequencing ('GénoLim platform' of the Limoges University, France). Sequenced reads were subsequently mapped to S μ and σ δ regions using the BLAST algorithm. The computational tool developed for experiments performs junction assembly, identifies break points in S μ and σ δ , identifies junction structures (blunt, micro-homology or junctions with insertions) and outputs a statistical summary of the identified junctions.
In 3′RR-deficient mice, among 4 904 163 raw reads, 39 046 reads were mapped to a switch junction, and the presence of 190 unique S μ -σ δ junctions was documented. The number of unique junctions (that is, clonally independent) was indeed dependent on the biological frequency of this CSR event in the studied samples. A summary of these 190 independent junctions provided a description of the S μ -σ δ CSR sequences in 3′RR-deficient mice at an unprecedented level. Until recently, only a few S μ -σ δ CSR sequences have been reported after cloning and subsequent sequencing using Sanger's method. 4 In the present study, the positions of IgD junctions (in terms of distance from S μ and σ δ ) and their structural profiles (blunt, microhomology or junction with insertions) were similar to those previously reported for wt mice. 7 These results undoubtedly demonstrate that IgD CSR markedly differs from conventional IgG, IgA and IgE CSR, reflecting the fact that IgD CSR is totally independent on the presence of the 3′RR super-enhancer. Furthermore, these results also show that μ-δ CSR is regulated and that double-strand breaks for S μ -σ δ CSR are not random breaks. The structural profiles of IgD junctions revealed a majority of junctions with micro-homology or insertions compared to blunt junctions, that is, a junctional pattern that markedly differs from IgG, IgA and IgE CSR. Such junctional bias is strongly reminiscent of the junctions produced by the alternative end-joining (A-EJ) pathway rather than the classical non-homologous DNA end-joining (C-NHEJ) pathway used for IgG, IgA and IgE CSR. 9 These results are consistent with the elevated IgD CSR in 53BP1-deficient mice, 5 since in the absence of 53BP1, AID-dependent DNA doublestrand breaks are repaired via the A-EJ pathway. Finally, in an intense unspecific inflammatory state (pristane injection), the phenotype of IgD junctions toward an A-EJ process was reinforced. In conclusion, double-strand breaks generated during IgG, IgA and IgE CSR are predominantly repaired through the C-NHEJ pathway, whereas for IgD CSR, there is a shift of DNA end repair to the auxiliary A-EJ pathway. At this time, the contribution of homologous recombination in IgD CSR remains an open question.
Not only trans but also cis molecular signals that mediate IgD CSR remain elusive. Since transcription is the primum movens of CSR, which cis-regulatory IgH enhancer (if any) may be implicated in the control of IgD CSR? Clearly, the 3′RR super-enhancer that controls conventional CSR is not involved in this particular IgH recombination. The IgH intronic E μ enhancer, previously reported to control VDJ recombination but not CSR, might be an appropriate candidate. Understanding the nature of the transcriptional enhancer that activates the regulation of IgD CSR remains an exciting challenge.
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